Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platinum Sensitive Relapsed Ovarian Cancer Clear all
Completed Phase 2 Interventional

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

NCT00325351
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sagopilone (ZK 219477) + carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00086892
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cetuximab, carboplatin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 64 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 10:12 PM EDT
Recruiting Phase 1 Interventional

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

NCT05942300
View directory record Official record
Conditions
Recurrent Ovarian Cancer
Interventions
CPI-0209, carboplatin
Drug
Lead sponsor
Lan Coffman
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270
View directory record Official record
Conditions
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

NCT02983799
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

NCT04377087
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib
Drug
Lead sponsor
Sarah E Taylor
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01001910
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

NCT00043082
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
carboplatin, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 23, 2026, 10:12 PM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

NCT00317434
View directory record Official record
Conditions
Ovarian Cancer
Interventions
lapatinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Birmingham, Alabama • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01459380
View directory record Official record
Conditions
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Veliparib
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
Aurora, Colorado • Augusta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

NCT01968213
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Rucaparib, Placebo
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Extension Study of the Efficacy of MORAb-003

NCT01018563
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
MORAb-003
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00023712
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
bortezomib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

NCT02855944
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Chemotherapy, Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study LY2228820 for Recurrent Ovarian Cancer

NCT01663857
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
LY2228820, Carboplatin, Placebo, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Sarasota, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Early Phase 1 Interventional

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

NCT04457089
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Interventions
Simvastatin 40mg
Drug
Lead sponsor
Marc Goodman
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

NCT00002600
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

NCT01281514
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Withdrawn Phase 3 Interventional

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

NCT03632798
View directory record Official record
Conditions
Recurrent Ovarian Cancer
Interventions
ChemoID assay, Chemotherapy
Diagnostic Test · Drug
Lead sponsor
Cordgenics, LLC
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Jackson, Mississippi • Charleston, West Virginia • Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 23, 2026, 10:12 PM EDT